#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0276] As is also disclosed in U.S.
1-1	0-1	[	_	_	
1-2	1-5	0276	_	_	
1-3	5-6	]	_	_	
1-4	7-9	As	_	_	
1-5	10-12	is	_	_	
1-6	13-17	also	_	_	
1-7	18-27	disclosed	_	_	
1-8	28-30	in	_	_	
1-9	31-34	U.S	_	_	
1-10	34-35	.	_	_	

#Text=Pat.
2-1	36-39	Pat	_	_	
2-2	39-40	.	_	_	

#Text=No. 6,541,509, "The synergistic combination described herein may be useful for treating neoplasia in a subject in need of treatment.
3-1	41-43	No	_	_	
3-2	43-44	.	_	_	
3-3	45-54	6,541,509	_	_	
3-4	54-55	,	_	_	
3-5	56-57	"	_	_	
3-6	57-60	The	_	_	
3-7	61-72	synergistic	_	_	
3-8	73-84	combination	_	_	
3-9	85-94	described	_	_	
3-10	95-101	herein	_	_	
3-11	102-105	may	_	_	
3-12	106-108	be	_	_	
3-13	109-115	useful	_	_	
3-14	116-119	for	_	_	
3-15	120-128	treating	_	_	
3-16	129-138	neoplasia	_	_	
3-17	139-141	in	_	_	
3-18	142-143	a	_	_	
3-19	144-151	subject	_	_	
3-20	152-154	in	_	_	
3-21	155-159	need	_	_	
3-22	160-162	of	_	_	
3-23	163-172	treatment	_	_	
3-24	172-173	.	_	_	

#Text=Paclitaxel and discodermolide, which comprise the synergistic combination of the present invention, may be co-administered to a subject concurrently, sequentially, or alternately, as described above.
4-1	174-184	Paclitaxel	_	_	
4-2	185-188	and	_	_	
4-3	189-203	discodermolide	_	_	
4-4	203-204	,	_	_	
4-5	205-210	which	_	_	
4-6	211-219	comprise	_	_	
4-7	220-223	the	_	_	
4-8	224-235	synergistic	_	_	
4-9	236-247	combination	_	_	
4-10	248-250	of	_	_	
4-11	251-254	the	_	_	
4-12	255-262	present	_	_	
4-13	263-272	invention	_	_	
4-14	272-273	,	_	_	
4-15	274-277	may	_	_	
4-16	278-280	be	_	_	
4-17	281-296	co-administered	_	_	
4-18	297-299	to	_	_	
4-19	300-301	a	_	_	
4-20	302-309	subject	_	_	
4-21	310-322	concurrently	_	_	
4-22	322-323	,	_	_	
4-23	324-336	sequentially	_	_	
4-24	336-337	,	_	_	
4-25	338-340	or	_	_	
4-26	341-352	alternately	_	_	
4-27	352-353	,	_	_	
4-28	354-356	as	_	_	
4-29	357-366	described	_	_	
4-30	367-372	above	_	_	
4-31	372-373	.	_	_	

#Text=Moreover, the paclitaxel and discodermolide of the present invention may be administered to a subject by any of the methods, and in any of the formulations, described above."
5-1	374-382	Moreover	_	_	
5-2	382-383	,	_	_	
5-3	384-387	the	_	_	
5-4	388-398	paclitaxel	_	_	
5-5	399-402	and	_	_	
5-6	403-417	discodermolide	_	_	
5-7	418-420	of	_	_	
5-8	421-424	the	_	_	
5-9	425-432	present	_	_	
5-10	433-442	invention	_	_	
5-11	443-446	may	_	_	
5-12	447-449	be	_	_	
5-13	450-462	administered	_	_	
5-14	463-465	to	_	_	
5-15	466-467	a	_	_	
5-16	468-475	subject	_	_	
5-17	476-478	by	_	_	
5-18	479-482	any	_	_	
5-19	483-485	of	_	_	
5-20	486-489	the	_	_	
5-21	490-497	methods	_	_	
5-22	497-498	,	_	_	
5-23	499-502	and	_	_	
5-24	503-505	in	_	_	
5-25	506-509	any	_	_	
5-26	510-512	of	_	_	
5-27	513-516	the	_	_	
5-28	517-529	formulations	_	_	
5-29	529-530	,	_	_	
5-30	531-540	described	_	_	
5-31	541-546	above	_	_	
5-32	546-547	.	_	_	
5-33	547-548	"	_	_	

#Text=These comments are equally applicable to the process of the instant invention, in which discodermolide is replaced by the magnetic anti-mitotic compound of this invention
#Text=[0277] By way of yet further illustration, and referring to published U.S. patent application 2003/0235855 (the entire disclosure of which is hereby incorporated by reference into this specification), claims an assay for the detection of paclitaxel resistant cells in human tumors.
6-1	549-554	These	_	_	
6-2	555-563	comments	_	_	
6-3	564-567	are	_	_	
6-4	568-575	equally	_	_	
6-5	576-586	applicable	_	_	
6-6	587-589	to	_	_	
6-7	590-593	the	_	_	
6-8	594-601	process	_	_	
6-9	602-604	of	_	_	
6-10	605-608	the	_	_	
6-11	609-616	instant	_	_	
6-12	617-626	invention	_	_	
6-13	626-627	,	_	_	
6-14	628-630	in	_	_	
6-15	631-636	which	_	_	
6-16	637-651	discodermolide	_	_	
6-17	652-654	is	_	_	
6-18	655-663	replaced	_	_	
6-19	664-666	by	_	_	
6-20	667-670	the	_	_	
6-21	671-679	magnetic	_	_	
6-22	680-692	anti-mitotic	_	_	
6-23	693-701	compound	_	_	
6-24	702-704	of	_	_	
6-25	705-709	this	_	_	
6-26	710-719	invention	_	_	
6-27	720-721	[	_	_	
6-28	721-725	0277	_	_	
6-29	725-726	]	_	_	
6-30	727-729	By	_	_	
6-31	730-733	way	_	_	
6-32	734-736	of	_	_	
6-33	737-740	yet	_	_	
6-34	741-748	further	_	_	
6-35	749-761	illustration	_	_	
6-36	761-762	,	_	_	
6-37	763-766	and	_	_	
6-38	767-776	referring	_	_	
6-39	777-779	to	_	_	
6-40	780-789	published	_	_	
6-41	790-793	U.S	_	_	
6-42	793-794	.	_	_	
6-43	795-801	patent	_	_	
6-44	802-813	application	_	_	
6-45	814-818	2003	_	_	
6-46	818-819	/	_	_	
6-47	819-826	0235855	_	_	
6-48	827-828	(	_	_	
6-49	828-831	the	_	_	
6-50	832-838	entire	_	_	
6-51	839-849	disclosure	_	_	
6-52	850-852	of	_	_	
6-53	853-858	which	_	_	
6-54	859-861	is	_	_	
6-55	862-868	hereby	_	_	
6-56	869-881	incorporated	_	_	
6-57	882-884	by	_	_	
6-58	885-894	reference	_	_	
6-59	895-899	into	_	_	
6-60	900-904	this	_	_	
6-61	905-918	specification	_	_	
6-62	918-919	)	_	_	
6-63	919-920	,	_	_	
6-64	921-927	claims	_	_	
6-65	928-930	an	_	_	
6-66	931-936	assay	_	_	
6-67	937-940	for	_	_	
6-68	941-944	the	_	_	
6-69	945-954	detection	_	_	
6-70	955-957	of	_	_	
6-71	958-968	paclitaxel	_	_	
6-72	969-978	resistant	_	_	
6-73	979-984	cells	_	_	
6-74	985-987	in	_	_	
6-75	988-993	human	_	_	
6-76	994-1000	tumors	_	_	
6-77	1000-1001	.	_	_	

#Text=Claim 4 of this published patent application, which is typical, claims: "An isolated tubulin amino acid sequence comprising an amino acid sequence having at least one mutation, the mutation selected from the group consisting of a mutation at position 210, a mutation at position 214, a mutation at position 215, a mutation at position 216, a mutation at position 217, a mutation at position 225, a mutation at position 228, a mutation at position 270, a mutation at position 273, a mutation at position 292, and a mutation at position 365 and any combination thereof."
#Text=[0278] At page 1 of published U.S. patent application 2003/0235855, the importance of paclitaxel is discussed.
7-1	1002-1007	Claim	_	_	
7-2	1008-1009	4	_	_	
7-3	1010-1012	of	_	_	
7-4	1013-1017	this	_	_	
7-5	1018-1027	published	_	_	
7-6	1028-1034	patent	_	_	
7-7	1035-1046	application	_	_	
7-8	1046-1047	,	_	_	
7-9	1048-1053	which	_	_	
7-10	1054-1056	is	_	_	
7-11	1057-1064	typical	_	_	
7-12	1064-1065	,	_	_	
7-13	1066-1072	claims	_	_	
7-14	1072-1073	:	_	_	
7-15	1074-1075	"	_	_	
7-16	1075-1077	An	_	_	
7-17	1078-1086	isolated	_	_	
7-18	1087-1094	tubulin	_	_	
7-19	1095-1100	amino	_	_	
7-20	1101-1105	acid	_	_	
7-21	1106-1114	sequence	_	_	
7-22	1115-1125	comprising	_	_	
7-23	1126-1128	an	_	_	
7-24	1129-1134	amino	_	_	
7-25	1135-1139	acid	_	_	
7-26	1140-1148	sequence	_	_	
7-27	1149-1155	having	_	_	
7-28	1156-1158	at	_	_	
7-29	1159-1164	least	_	_	
7-30	1165-1168	one	_	_	
7-31	1169-1177	mutation	_	_	
7-32	1177-1178	,	_	_	
7-33	1179-1182	the	_	_	
7-34	1183-1191	mutation	_	_	
7-35	1192-1200	selected	_	_	
7-36	1201-1205	from	_	_	
7-37	1206-1209	the	_	_	
7-38	1210-1215	group	_	_	
7-39	1216-1226	consisting	_	_	
7-40	1227-1229	of	_	_	
7-41	1230-1231	a	_	_	
7-42	1232-1240	mutation	_	_	
7-43	1241-1243	at	_	_	
7-44	1244-1252	position	_	_	
7-45	1253-1256	210	_	_	
7-46	1256-1257	,	_	_	
7-47	1258-1259	a	_	_	
7-48	1260-1268	mutation	_	_	
7-49	1269-1271	at	_	_	
7-50	1272-1280	position	_	_	
7-51	1281-1284	214	_	_	
7-52	1284-1285	,	_	_	
7-53	1286-1287	a	_	_	
7-54	1288-1296	mutation	_	_	
7-55	1297-1299	at	_	_	
7-56	1300-1308	position	_	_	
7-57	1309-1312	215	_	_	
7-58	1312-1313	,	_	_	
7-59	1314-1315	a	_	_	
7-60	1316-1324	mutation	_	_	
7-61	1325-1327	at	_	_	
7-62	1328-1336	position	_	_	
7-63	1337-1340	216	_	_	
7-64	1340-1341	,	_	_	
7-65	1342-1343	a	_	_	
7-66	1344-1352	mutation	_	_	
7-67	1353-1355	at	_	_	
7-68	1356-1364	position	_	_	
7-69	1365-1368	217	_	_	
7-70	1368-1369	,	_	_	
7-71	1370-1371	a	_	_	
7-72	1372-1380	mutation	_	_	
7-73	1381-1383	at	_	_	
7-74	1384-1392	position	_	_	
7-75	1393-1396	225	_	_	
7-76	1396-1397	,	_	_	
7-77	1398-1399	a	_	_	
7-78	1400-1408	mutation	_	_	
7-79	1409-1411	at	_	_	
7-80	1412-1420	position	_	_	
7-81	1421-1424	228	_	_	
7-82	1424-1425	,	_	_	
7-83	1426-1427	a	_	_	
7-84	1428-1436	mutation	_	_	
7-85	1437-1439	at	_	_	
7-86	1440-1448	position	_	_	
7-87	1449-1452	270	_	_	
7-88	1452-1453	,	_	_	
7-89	1454-1455	a	_	_	
7-90	1456-1464	mutation	_	_	
7-91	1465-1467	at	_	_	
7-92	1468-1476	position	_	_	
7-93	1477-1480	273	_	_	
7-94	1480-1481	,	_	_	
7-95	1482-1483	a	_	_	
7-96	1484-1492	mutation	_	_	
7-97	1493-1495	at	_	_	
7-98	1496-1504	position	_	_	
7-99	1505-1508	292	_	_	
7-100	1508-1509	,	_	_	
7-101	1510-1513	and	_	_	
7-102	1514-1515	a	_	_	
7-103	1516-1524	mutation	_	_	
7-104	1525-1527	at	_	_	
7-105	1528-1536	position	_	_	
7-106	1537-1540	365	_	_	
7-107	1541-1544	and	_	_	
7-108	1545-1548	any	_	_	
7-109	1549-1560	combination	_	_	
7-110	1561-1568	thereof	_	_	
7-111	1568-1569	.	_	_	
7-112	1569-1570	"	_	_	
7-113	1571-1572	[	_	_	
7-114	1572-1576	0278	_	_	
7-115	1576-1577	]	_	_	
7-116	1578-1580	At	_	_	
7-117	1581-1585	page	_	_	
7-118	1586-1587	1	_	_	
7-119	1588-1590	of	_	_	
7-120	1591-1600	published	_	_	
7-121	1601-1604	U.S	_	_	
7-122	1604-1605	.	_	_	
7-123	1606-1612	patent	_	_	
7-124	1613-1624	application	_	_	
7-125	1625-1629	2003	_	_	
7-126	1629-1630	/	_	_	
7-127	1630-1637	0235855	_	_	
7-128	1637-1638	,	_	_	
7-129	1639-1642	the	_	_	
7-130	1643-1653	importance	_	_	
7-131	1654-1656	of	_	_	
7-132	1657-1667	paclitaxel	_	_	
7-133	1668-1670	is	_	_	
7-134	1671-1680	discussed	_	_	
7-135	1680-1681	.	_	_	

#Text=It is disclosed that "Paclitaxel (Taxol), Taxotere and other paclitaxel-like drugs that are currently under development hold great promise for the treatment of human cancer.
8-1	1682-1684	It	_	_	
8-2	1685-1687	is	_	_	
8-3	1688-1697	disclosed	_	_	
8-4	1698-1702	that	_	_	
8-5	1703-1704	"	_	_	
8-6	1704-1714	Paclitaxel	_	_	
8-7	1715-1716	(	_	_	
8-8	1716-1721	Taxol	_	_	
8-9	1721-1722	)	_	_	
8-10	1722-1723	,	_	_	
8-11	1724-1732	Taxotere	_	_	
8-12	1733-1736	and	_	_	
8-13	1737-1742	other	_	_	
8-14	1743-1758	paclitaxel-like	_	_	
8-15	1759-1764	drugs	_	_	
8-16	1765-1769	that	_	_	
8-17	1770-1773	are	_	_	
8-18	1774-1783	currently	_	_	
8-19	1784-1789	under	_	_	
8-20	1790-1801	development	_	_	
8-21	1802-1806	hold	_	_	
8-22	1807-1812	great	_	_	
8-23	1813-1820	promise	_	_	
8-24	1821-1824	for	_	_	
8-25	1825-1828	the	_	_	
8-26	1829-1838	treatment	_	_	
8-27	1839-1841	of	_	_	
8-28	1842-1847	human	_	_	
8-29	1848-1854	cancer	_	_	
8-30	1854-1855	.	_	_	

#Text=Paclitaxel has shown remarkable activity against breast and ovarian cancer, melanomas, non-small lung carcinoma, esophogeal cancer, Kaposi's sarcoma, and some hematological malignancies.
9-1	1856-1866	Paclitaxel	_	_	
9-2	1867-1870	has	_	_	
9-3	1871-1876	shown	_	_	
9-4	1877-1887	remarkable	_	_	
9-5	1888-1896	activity	_	_	
9-6	1897-1904	against	_	_	
9-7	1905-1911	breast	_	_	
9-8	1912-1915	and	_	_	
9-9	1916-1923	ovarian	_	_	
9-10	1924-1930	cancer	_	_	
9-11	1930-1931	,	_	_	
9-12	1932-1941	melanomas	_	_	
9-13	1941-1942	,	_	_	
9-14	1943-1952	non-small	_	_	
9-15	1953-1957	lung	_	_	
9-16	1958-1967	carcinoma	_	_	
9-17	1967-1968	,	_	_	
9-18	1969-1979	esophogeal	_	_	
9-19	1980-1986	cancer	_	_	
9-20	1986-1987	,	_	_	
9-21	1988-1996	Kaposi's	_	_	
9-22	1997-2004	sarcoma	_	_	
9-23	2004-2005	,	_	_	
9-24	2006-2009	and	_	_	
9-25	2010-2014	some	_	_	
9-26	2015-2028	hematological	_	_	
9-27	2029-2041	malignancies	_	_	
9-28	2041-2042	.	_	_	

#Text=It has been described as the most significant antitumor drug developed in the last several decades and will, without doubt, find widespread use in the treatment of cancer.
10-1	2043-2045	It	_	_	
10-2	2046-2049	has	_	_	
10-3	2050-2054	been	_	_	
10-4	2055-2064	described	_	_	
10-5	2065-2067	as	_	_	
10-6	2068-2071	the	_	_	
10-7	2072-2076	most	_	_	
10-8	2077-2088	significant	_	_	
10-9	2089-2098	antitumor	_	_	
10-10	2099-2103	drug	_	_	
10-11	2104-2113	developed	_	_	
10-12	2114-2116	in	_	_	
10-13	2117-2120	the	_	_	
10-14	2121-2125	last	_	_	
10-15	2126-2133	several	_	_	
10-16	2134-2141	decades	_	_	
10-17	2142-2145	and	_	_	
10-18	2146-2150	will	_	_	
10-19	2150-2151	,	_	_	
10-20	2152-2159	without	_	_	
10-21	2160-2165	doubt	_	_	
10-22	2165-2166	,	_	_	
10-23	2167-2171	find	_	_	
10-24	2172-2182	widespread	_	_	
10-25	2183-2186	use	_	_	
10-26	2187-2189	in	_	_	
10-27	2190-2193	the	_	_	
10-28	2194-2203	treatment	_	_	
10-29	2204-2206	of	_	_	
10-30	2207-2213	cancer	_	_	
10-31	2213-2214	.	_	_	

#Text=However, as is true of virtually all cancer chemotherapeutic drugs, patients responsive to paclitaxel eventually relapse due to the emergence of drug resistant tumor cells.
11-1	2215-2222	However	*[1]	13-5[2_1]	
11-2	2222-2223	,	*[1]	_	
11-3	2224-2226	as	*[1]	_	
11-4	2227-2229	is	*[1]	_	
11-5	2230-2234	true	*[1]	_	
11-6	2235-2237	of	*[1]	_	
11-7	2238-2247	virtually	*[1]	_	
11-8	2248-2251	all	*[1]	_	
11-9	2252-2258	cancer	*[1]	_	
11-10	2259-2275	chemotherapeutic	*[1]	_	
11-11	2276-2281	drugs	*[1]	_	
11-12	2281-2282	,	*[1]	_	
11-13	2283-2291	patients	*[1]	_	
11-14	2292-2302	responsive	*[1]	_	
11-15	2303-2305	to	*[1]	_	
11-16	2306-2316	paclitaxel	*[1]	_	
11-17	2317-2327	eventually	*[1]	_	
11-18	2328-2335	relapse	*[1]	_	
11-19	2336-2339	due	*[1]	_	
11-20	2340-2342	to	*[1]	_	
11-21	2343-2346	the	*[1]	_	
11-22	2347-2356	emergence	*[1]	_	
11-23	2357-2359	of	*[1]	_	
11-24	2360-2364	drug	*[1]	_	
11-25	2365-2374	resistant	*[1]	_	
11-26	2375-2380	tumor	*[1]	_	
11-27	2381-2386	cells	*[1]	_	
11-28	2386-2387	.	*[1]	_	

#Text=Thus, there is a need in the art for methods to identify paclitaxel-resistant tumor cells, for agents that allow such identifications in a simple and cost effective way, and for methods for to treat patients with paclitaxel resistant tumor cells."
12-1	2388-2392	Thus	_	_	
12-2	2392-2393	,	_	_	
12-3	2394-2399	there	_	_	
12-4	2400-2402	is	_	_	
12-5	2403-2404	a	_	_	
12-6	2405-2409	need	_	_	
12-7	2410-2412	in	_	_	
12-8	2413-2416	the	_	_	
12-9	2417-2420	art	_	_	
12-10	2421-2424	for	_	_	
12-11	2425-2432	methods	_	_	
12-12	2433-2435	to	_	_	
12-13	2436-2444	identify	_	_	
12-14	2445-2465	paclitaxel-resistant	_	_	
12-15	2466-2471	tumor	_	_	
12-16	2472-2477	cells	_	_	
12-17	2477-2478	,	_	_	
12-18	2479-2482	for	_	_	
12-19	2483-2489	agents	_	_	
12-20	2490-2494	that	_	_	
12-21	2495-2500	allow	_	_	
12-22	2501-2505	such	_	_	
12-23	2506-2521	identifications	_	_	
12-24	2522-2524	in	_	_	
12-25	2525-2526	a	_	_	
12-26	2527-2533	simple	_	_	
12-27	2534-2537	and	_	_	
12-28	2538-2542	cost	_	_	
12-29	2543-2552	effective	_	_	
12-30	2553-2556	way	_	_	
12-31	2556-2557	,	_	_	
12-32	2558-2561	and	_	_	
12-33	2562-2565	for	_	_	
12-34	2566-2573	methods	_	_	
12-35	2574-2577	for	_	_	
12-36	2578-2580	to	_	_	
12-37	2581-2586	treat	_	_	
12-38	2587-2595	patients	_	_	
12-39	2596-2600	with	_	_	
12-40	2601-2611	paclitaxel	_	_	
12-41	2612-2621	resistant	_	_	
12-42	2622-2627	tumor	_	_	
12-43	2628-2633	cells	_	_	
12-44	2633-2634	.	_	_	
12-45	2634-2635	"	_	_	

#Text=The solution presented to this problem in such published patent application is also described at page 1 thereof, wherein it is stated that: "The present invention involves polynucleotide mutations which confer paclitaxel resistance; mutant cells which are paclitaxel resistant; and methods to determine paclitaxel resistance.
13-1	2636-2639	The	_	_	
13-2	2640-2648	solution	_	_	
13-3	2649-2658	presented	_	_	
13-4	2659-2661	to	_	_	
13-5	2662-2666	this	*[2]	_	
13-6	2667-2674	problem	*[2]	_	
13-7	2675-2677	in	_	_	
13-8	2678-2682	such	_	_	
13-9	2683-2692	published	_	_	
13-10	2693-2699	patent	_	_	
13-11	2700-2711	application	_	_	
13-12	2712-2714	is	_	_	
13-13	2715-2719	also	_	_	
13-14	2720-2729	described	_	_	
13-15	2730-2732	at	_	_	
13-16	2733-2737	page	_	_	
13-17	2738-2739	1	_	_	
13-18	2740-2747	thereof	_	_	
13-19	2747-2748	,	_	_	
13-20	2749-2756	wherein	_	_	
13-21	2757-2759	it	_	_	
13-22	2760-2762	is	_	_	
13-23	2763-2769	stated	_	_	
13-24	2770-2774	that	_	_	
13-25	2774-2775	:	_	_	
13-26	2776-2777	"	_	_	
13-27	2777-2780	The	_	_	
13-28	2781-2788	present	_	_	
13-29	2789-2798	invention	_	_	
13-30	2799-2807	involves	_	_	
13-31	2808-2822	polynucleotide	_	_	
13-32	2823-2832	mutations	_	_	
13-33	2833-2838	which	_	_	
13-34	2839-2845	confer	_	_	
13-35	2846-2856	paclitaxel	_	_	
13-36	2857-2867	resistance	_	_	
13-37	2867-2868	;	_	_	
13-38	2869-2875	mutant	_	_	
13-39	2876-2881	cells	_	_	
13-40	2882-2887	which	_	_	
13-41	2888-2891	are	_	_	
13-42	2892-2902	paclitaxel	_	_	
13-43	2903-2912	resistant	_	_	
13-44	2912-2913	;	_	_	
13-45	2914-2917	and	_	_	
13-46	2918-2925	methods	_	_	
13-47	2926-2928	to	_	_	
13-48	2929-2938	determine	_	_	
13-49	2939-2949	paclitaxel	_	_	
13-50	2950-2960	resistance	_	_	
13-51	2960-2961	.	_	_	

#Text=The present invention also provides a simple assay with sufficient sensitivity to detect drug resistant cells in tumor biopsies by extracting polynucleotide from the tissue.
14-1	2962-2965	The	_	_	
14-2	2966-2973	present	_	_	
14-3	2974-2983	invention	_	_	
14-4	2984-2988	also	_	_	
14-5	2989-2997	provides	_	_	
14-6	2998-2999	a	_	_	
14-7	3000-3006	simple	_	_	
14-8	3007-3012	assay	_	_	
14-9	3013-3017	with	_	_	
14-10	3018-3028	sufficient	_	_	
14-11	3029-3040	sensitivity	_	_	
14-12	3041-3043	to	_	_	
14-13	3044-3050	detect	_	_	
14-14	3051-3055	drug	_	_	
14-15	3056-3065	resistant	_	_	
14-16	3066-3071	cells	_	_	
14-17	3072-3074	in	_	_	
14-18	3075-3080	tumor	_	_	
14-19	3081-3089	biopsies	_	_	
14-20	3090-3092	by	_	_	
14-21	3093-3103	extracting	_	_	
14-22	3104-3118	polynucleotide	_	_	
14-23	3119-3123	from	_	_	
14-24	3124-3127	the	_	_	
14-25	3128-3134	tissue	_	_	
14-26	3134-3135	.	_	_	

#Text=The extracted polynucleotide is then hybridized to mutant-specific PCR primers and the mutant regions of tubulin are identified by selective amplification.
15-1	3136-3139	The	_	_	
15-2	3140-3149	extracted	_	_	
15-3	3150-3164	polynucleotide	_	_	
15-4	3165-3167	is	_	_	
15-5	3168-3172	then	_	_	
15-6	3173-3183	hybridized	_	_	
15-7	3184-3186	to	_	_	
15-8	3187-3202	mutant-specific	_	_	
15-9	3203-3206	PCR	_	_	
15-10	3207-3214	primers	_	_	
15-11	3215-3218	and	_	_	
15-12	3219-3222	the	_	_	
15-13	3223-3229	mutant	_	_	
15-14	3230-3237	regions	_	_	
15-15	3238-3240	of	_	_	
15-16	3241-3248	tubulin	_	_	
15-17	3249-3252	are	_	_	
15-18	3253-3263	identified	_	_	
15-19	3264-3266	by	_	_	
15-20	3267-3276	selective	_	_	
15-21	3277-3290	amplification	_	_	
15-22	3290-3291	.	_	_	

#Text=Once identified, a secondary treatment protocol can be administered to the patient to aid in tumor treatment."
#Text=[0279] At pages 2 et seq. of published U.S. patent application 2003/00235855, the inventor discloses that " . . . mutations able to conver resistance to paclitaxel are clustered in several small regions of beta-tubulin."
16-1	3292-3296	Once	_	_	
16-2	3297-3307	identified	_	_	
16-3	3307-3308	,	_	_	
16-4	3309-3310	a	_	_	
16-5	3311-3320	secondary	_	_	
16-6	3321-3330	treatment	_	_	
16-7	3331-3339	protocol	_	_	
16-8	3340-3343	can	_	_	
16-9	3344-3346	be	_	_	
16-10	3347-3359	administered	_	_	
16-11	3360-3362	to	_	_	
16-12	3363-3366	the	_	_	
16-13	3367-3374	patient	_	_	
16-14	3375-3377	to	_	_	
16-15	3378-3381	aid	_	_	
16-16	3382-3384	in	_	_	
16-17	3385-3390	tumor	_	_	
16-18	3391-3400	treatment	_	_	
16-19	3400-3401	.	_	_	
16-20	3401-3402	"	_	_	
16-21	3403-3404	[	_	_	
16-22	3404-3408	0279	_	_	
16-23	3408-3409	]	_	_	
16-24	3410-3412	At	_	_	
16-25	3413-3418	pages	_	_	
16-26	3419-3420	2	_	_	
16-27	3421-3423	et	_	_	
16-28	3424-3427	seq	_	_	
16-29	3427-3428	.	_	_	
16-30	3429-3431	of	_	_	
16-31	3432-3441	published	_	_	
16-32	3442-3445	U.S	_	_	
16-33	3445-3446	.	_	_	
16-34	3447-3453	patent	_	_	
16-35	3454-3465	application	_	_	
16-36	3466-3470	2003	_	_	
16-37	3470-3471	/	_	_	
16-38	3471-3479	00235855	_	_	
16-39	3479-3480	,	_	_	
16-40	3481-3484	the	_	_	
16-41	3485-3493	inventor	_	_	
16-42	3494-3503	discloses	_	_	
16-43	3504-3508	that	_	_	
16-44	3509-3510	"	_	_	
16-45	3511-3512	.	_	_	
16-46	3513-3514	.	_	_	
16-47	3515-3516	.	_	_	
16-48	3517-3526	mutations	_	_	
16-49	3527-3531	able	_	_	
16-50	3532-3534	to	_	_	
16-51	3535-3541	conver	_	_	
16-52	3542-3552	resistance	_	_	
16-53	3553-3555	to	_	_	
16-54	3556-3566	paclitaxel	_	_	
16-55	3567-3570	are	_	_	
16-56	3571-3580	clustered	_	_	
16-57	3581-3583	in	_	_	
16-58	3584-3591	several	_	_	
16-59	3592-3597	small	_	_	
16-60	3598-3605	regions	_	_	
16-61	3606-3608	of	_	_	
16-62	3609-3621	beta-tubulin	_	_	
16-63	3621-3622	.	_	_	
16-64	3622-3623	"	_	_	

#Text=In paragraphs 0022 et seq., it is disclosed that: "The inventor has found that mutations able to confer resistance to paclitaxel are clustered in several small regions of .beta.
17-1	3624-3626	In	_	_	
17-2	3627-3637	paragraphs	_	_	
17-3	3638-3642	0022	_	_	
17-4	3643-3645	et	_	_	
17-5	3646-3649	seq	_	_	
17-6	3649-3650	.	_	_	
17-7	3650-3651	,	_	_	
17-8	3652-3654	it	_	_	
17-9	3655-3657	is	_	_	
17-10	3658-3667	disclosed	_	_	
17-11	3668-3672	that	_	_	
17-12	3672-3673	:	_	_	
17-13	3674-3675	"	_	_	
17-14	3675-3678	The	_	_	
17-15	3679-3687	inventor	_	_	
17-16	3688-3691	has	_	_	
17-17	3692-3697	found	_	_	
17-18	3698-3702	that	_	_	
17-19	3703-3712	mutations	_	_	
17-20	3713-3717	able	_	_	
17-21	3718-3720	to	_	_	
17-22	3721-3727	confer	_	_	
17-23	3728-3738	resistance	_	_	
17-24	3739-3741	to	_	_	
17-25	3742-3752	paclitaxel	_	_	
17-26	3753-3756	are	_	_	
17-27	3757-3766	clustered	_	_	
17-28	3767-3769	in	_	_	
17-29	3770-3777	several	_	_	
17-30	3778-3783	small	_	_	
17-31	3784-3791	regions	_	_	
17-32	3792-3794	of	_	_	
17-33	3795-3796	.	_	_	
17-34	3796-3800	beta	_	_	
17-35	3800-3801	.	_	_	

#Text=-tubulin (Tables I-III) including I210T, T214A, L215H, L215R, L215F, L215A, L215E, L215M, L215P, K216A, L217R, L217N, L217A, L225M, L228A, L228F, L228H, F270C, L273V, Q292H, and V365D.
18-1	3801-3802	-	_	_	
18-2	3802-3809	tubulin	_	_	
18-3	3810-3811	(	_	_	
18-4	3811-3817	Tables	_	_	
18-5	3818-3823	I-III	_	_	
18-6	3823-3824	)	_	_	
18-7	3825-3834	including	_	_	
18-8	3835-3840	I210T	_	_	
18-9	3840-3841	,	_	_	
18-10	3842-3847	T214A	_	_	
18-11	3847-3848	,	_	_	
18-12	3849-3854	L215H	_	_	
18-13	3854-3855	,	_	_	
18-14	3856-3861	L215R	_	_	
18-15	3861-3862	,	_	_	
18-16	3863-3868	L215F	_	_	
18-17	3868-3869	,	_	_	
18-18	3870-3875	L215A	_	_	
18-19	3875-3876	,	_	_	
18-20	3877-3882	L215E	_	_	
18-21	3882-3883	,	_	_	
18-22	3884-3889	L215M	_	_	
18-23	3889-3890	,	_	_	
18-24	3891-3896	L215P	_	_	
18-25	3896-3897	,	_	_	
18-26	3898-3903	K216A	_	_	
18-27	3903-3904	,	_	_	
18-28	3905-3910	L217R	_	_	
18-29	3910-3911	,	_	_	
18-30	3912-3917	L217N	_	_	
18-31	3917-3918	,	_	_	
18-32	3919-3924	L217A	_	_	
18-33	3924-3925	,	_	_	
18-34	3926-3931	L225M	_	_	
18-35	3931-3932	,	_	_	
18-36	3933-3938	L228A	_	_	
18-37	3938-3939	,	_	_	
18-38	3940-3945	L228F	_	_	
18-39	3945-3946	,	_	_	
18-40	3947-3952	L228H	_	_	
18-41	3952-3953	,	_	_	
18-42	3954-3959	F270C	_	_	
18-43	3959-3960	,	_	_	
18-44	3961-3966	L273V	_	_	
18-45	3966-3967	,	_	_	
18-46	3968-3973	Q292H	_	_	
18-47	3973-3974	,	_	_	
18-48	3975-3978	and	_	_	
18-49	3979-3984	V365D	_	_	
18-50	3984-3985	.	_	_	

#Text=Of these 21 identified and sequenced mutant tubulins, 15 or 62% have a substitution at leucine including locations 215, 217, 225, 228 and 273.
19-1	3986-3988	Of	_	_	
19-2	3989-3994	these	_	_	
19-3	3995-3997	21	_	_	
19-4	3998-4008	identified	_	_	
19-5	4009-4012	and	_	_	
19-6	4013-4022	sequenced	_	_	
19-7	4023-4029	mutant	_	_	
19-8	4030-4038	tubulins	_	_	
19-9	4038-4039	,	_	_	
19-10	4040-4042	15	_	_	
19-11	4043-4045	or	_	_	
19-12	4046-4049	62%	_	_	
19-13	4050-4054	have	_	_	
19-14	4055-4056	a	_	_	
19-15	4057-4069	substitution	_	_	
19-16	4070-4072	at	_	_	
19-17	4073-4080	leucine	_	_	
19-18	4081-4090	including	_	_	
19-19	4091-4100	locations	_	_	
19-20	4101-4104	215	_	_	
19-21	4104-4105	,	_	_	
19-22	4106-4109	217	_	_	
19-23	4109-4110	,	_	_	
19-24	4111-4114	225	_	_	
19-25	4114-4115	,	_	_	
19-26	4116-4119	228	_	_	
19-27	4120-4123	and	_	_	
19-28	4124-4127	273	_	_	
19-29	4127-4128	.	_	_	

#Text=Of the 15 total leucine mutants, 7 or 46.7% occur at leu215, 3 or 20% occur at leu217, 3 or 20% occur at leu228, 1 or 6.7% occur at leu225 and 1 or 6.7% occur at leu273.
20-1	4129-4131	Of	_	_	
20-2	4132-4135	the	_	_	
20-3	4136-4138	15	_	_	
20-4	4139-4144	total	_	_	
20-5	4145-4152	leucine	_	_	
20-6	4153-4160	mutants	_	_	
20-7	4160-4161	,	_	_	
20-8	4162-4163	7	_	_	
20-9	4164-4166	or	_	_	
20-10	4167-4172	46.7%	_	_	
20-11	4173-4178	occur	_	_	
20-12	4179-4181	at	_	_	
20-13	4182-4188	leu215	_	_	
20-14	4188-4189	,	_	_	
20-15	4190-4191	3	_	_	
20-16	4192-4194	or	_	_	
20-17	4195-4198	20%	_	_	
20-18	4199-4204	occur	_	_	
20-19	4205-4207	at	_	_	
20-20	4208-4214	leu217	_	_	
20-21	4214-4215	,	_	_	
20-22	4216-4217	3	_	_	
20-23	4218-4220	or	_	_	
20-24	4221-4224	20%	_	_	
20-25	4225-4230	occur	_	_	
20-26	4231-4233	at	_	_	
20-27	4234-4240	leu228	_	_	
20-28	4240-4241	,	_	_	
20-29	4242-4243	1	_	_	
20-30	4244-4246	or	_	_	
20-31	4247-4251	6.7%	_	_	
20-32	4252-4257	occur	_	_	
20-33	4258-4260	at	_	_	
20-34	4261-4267	leu225	_	_	
20-35	4268-4271	and	_	_	
20-36	4272-4273	1	_	_	
20-37	4274-4276	or	_	_	
20-38	4277-4281	6.7%	_	_	
20-39	4282-4287	occur	_	_	
20-40	4288-4290	at	_	_	
20-41	4291-4297	leu273	_	_	
20-42	4297-4298	.	_	_	

#Text=The ability of 19 of the 21 total mutations to confer paclitaxel resistance has been confirmed by transfecting mutant cDNAs into wild-type cells."
#Text=[0280] It is also disclosed in published U.S. patent application 2003/0235855 (commencing at page 3 thereof) that: "The clustering of mutations affecting leucines is unusual and unexpected.
21-1	4299-4302	The	_	_	
21-2	4303-4310	ability	_	_	
21-3	4311-4313	of	_	_	
21-4	4314-4316	19	_	_	
21-5	4317-4319	of	_	_	
21-6	4320-4323	the	_	_	
21-7	4324-4326	21	_	_	
21-8	4327-4332	total	_	_	
21-9	4333-4342	mutations	_	_	
21-10	4343-4345	to	_	_	
21-11	4346-4352	confer	_	_	
21-12	4353-4363	paclitaxel	_	_	
21-13	4364-4374	resistance	_	_	
21-14	4375-4378	has	_	_	
21-15	4379-4383	been	_	_	
21-16	4384-4393	confirmed	_	_	
21-17	4394-4396	by	_	_	
21-18	4397-4409	transfecting	_	_	
21-19	4410-4416	mutant	_	_	
21-20	4417-4422	cDNAs	_	_	
21-21	4423-4427	into	_	_	
21-22	4428-4437	wild-type	_	_	
21-23	4438-4443	cells	_	_	
21-24	4443-4444	.	_	_	
21-25	4444-4445	"	_	_	
21-26	4446-4447	[	_	_	
21-27	4447-4451	0280	_	_	
21-28	4451-4452	]	_	_	
21-29	4453-4455	It	_	_	
21-30	4456-4458	is	_	_	
21-31	4459-4463	also	_	_	
21-32	4464-4473	disclosed	_	_	
21-33	4474-4476	in	_	_	
21-34	4477-4486	published	_	_	
21-35	4487-4490	U.S	_	_	
21-36	4490-4491	.	_	_	
21-37	4492-4498	patent	_	_	
21-38	4499-4510	application	_	_	
21-39	4511-4515	2003	_	_	
21-40	4515-4516	/	_	_	
21-41	4516-4523	0235855	_	_	
21-42	4524-4525	(	_	_	
21-43	4525-4535	commencing	_	_	
21-44	4536-4538	at	_	_	
21-45	4539-4543	page	_	_	
21-46	4544-4545	3	_	_	
21-47	4546-4553	thereof	_	_	
21-48	4553-4554	)	_	_	
21-49	4555-4559	that	_	_	
21-50	4559-4560	:	_	_	
21-51	4561-4562	"	_	_	
21-52	4562-4565	The	_	_	
21-53	4566-4576	clustering	_	_	
21-54	4577-4579	of	_	_	
21-55	4580-4589	mutations	_	_	
21-56	4590-4599	affecting	_	_	
21-57	4600-4608	leucines	_	_	
21-58	4609-4611	is	_	_	
21-59	4612-4619	unusual	_	_	
21-60	4620-4623	and	_	_	
21-61	4624-4634	unexpected	_	_	
21-62	4634-4635	.	_	_	

#Text=Also unexpected is the three relatively localized regions of mutation, 210-217, 225-228, and 270-273, and two isolated sites of mutations, 292 and 365.
22-1	4636-4640	Also	_	_	
22-2	4641-4651	unexpected	_	_	
22-3	4652-4654	is	_	_	
22-4	4655-4658	the	_	_	
22-5	4659-4664	three	_	_	
22-6	4665-4675	relatively	_	_	
22-7	4676-4685	localized	_	_	
22-8	4686-4693	regions	_	_	
22-9	4694-4696	of	_	_	
22-10	4697-4705	mutation	_	_	
22-11	4705-4706	,	_	_	
22-12	4707-4710	210	_	_	
22-13	4710-4711	-	_	_	
22-14	4711-4714	217	_	_	
22-15	4714-4715	,	_	_	
22-16	4716-4719	225	_	_	
22-17	4719-4720	-	_	_	
22-18	4720-4723	228	_	_	
22-19	4723-4724	,	_	_	
22-20	4725-4728	and	_	_	
22-21	4729-4732	270	_	_	
22-22	4732-4733	-	_	_	
22-23	4733-4736	273	_	_	
22-24	4736-4737	,	_	_	
22-25	4738-4741	and	_	_	
22-26	4742-4745	two	_	_	
22-27	4746-4754	isolated	_	_	
22-28	4755-4760	sites	_	_	
22-29	4761-4763	of	_	_	
22-30	4764-4773	mutations	_	_	
22-31	4773-4774	,	_	_	
22-32	4775-4778	292	_	_	
22-33	4779-4782	and	_	_	
22-34	4783-4786	365	_	_	
22-35	4786-4787	.	_	_	

#Text=Although some of these regions appear distant in the primary structure, they are actually close together in the tertiary structure of .beta.
23-1	4788-4796	Although	_	_	
23-2	4797-4801	some	_	_	
23-3	4802-4804	of	_	_	
23-4	4805-4810	these	_	_	
23-5	4811-4818	regions	_	_	
23-6	4819-4825	appear	_	_	
23-7	4826-4833	distant	_	_	
23-8	4834-4836	in	_	_	
23-9	4837-4840	the	_	_	
23-10	4841-4848	primary	_	_	
23-11	4849-4858	structure	_	_	
23-12	4858-4859	,	_	_	
23-13	4860-4864	they	_	_	
23-14	4865-4868	are	_	_	
23-15	4869-4877	actually	_	_	
23-16	4878-4883	close	_	_	
23-17	4884-4892	together	_	_	
23-18	4893-4895	in	_	_	
23-19	4896-4899	the	_	_	
23-20	4900-4908	tertiary	_	_	
23-21	4909-4918	structure	_	_	
23-22	4919-4921	of	_	_	
23-23	4922-4923	.	_	_	
23-24	4923-4927	beta	_	_	
23-25	4927-4928	.	_	_	

#Text=-tubulin.
24-1	4928-4929	-	_	_	
24-2	4929-4936	tubulin	_	_	
24-3	4936-4937	.	_	_	

#Text=The data support the hypothesis that the mutations affect a critical interaction between tubulin subunits necessary for microtubule assembly and that the mechanism of paclitaxel is to facilitate this interaction."
25-1	4938-4941	The	_	_	
25-2	4942-4946	data	_	_	
25-3	4947-4954	support	_	_	
25-4	4955-4958	the	_	_	
25-5	4959-4969	hypothesis	_	_	
25-6	4970-4974	that	_	_	
25-7	4975-4978	the	_	_	
25-8	4979-4988	mutations	_	_	
25-9	4989-4995	affect	_	_	
25-10	4996-4997	a	_	_	
25-11	4998-5006	critical	_	_	
25-12	5007-5018	interaction	_	_	
25-13	5019-5026	between	_	_	
25-14	5027-5034	tubulin	_	_	
25-15	5035-5043	subunits	_	_	
25-16	5044-5053	necessary	_	_	
25-17	5054-5057	for	_	_	
25-18	5058-5069	microtubule	_	_	
25-19	5070-5078	assembly	_	_	
25-20	5079-5082	and	_	_	
25-21	5083-5087	that	_	_	
25-22	5088-5091	the	_	_	
25-23	5092-5101	mechanism	_	_	
25-24	5102-5104	of	_	_	
25-25	5105-5115	paclitaxel	_	_	
25-26	5116-5118	is	_	_	
25-27	5119-5121	to	_	_	
25-28	5122-5132	facilitate	_	_	
25-29	5133-5137	this	_	_	
25-30	5138-5149	interaction	_	_	
25-31	5149-5150	.	_	_	
25-32	5150-5151	"	_	_	

#Text=Thereafter, in the middle of page 3 of such patent application, Table 1 is presented.
26-1	5152-5162	Thereafter	_	_	
26-2	5162-5163	,	_	_	
26-3	5164-5166	in	_	_	
26-4	5167-5170	the	_	_	
26-5	5171-5177	middle	_	_	
26-6	5178-5180	of	_	_	
26-7	5181-5185	page	_	_	
26-8	5186-5187	3	_	_	
26-9	5188-5190	of	_	_	
26-10	5191-5195	such	_	_	
26-11	5196-5202	patent	_	_	
26-12	5203-5214	application	_	_	
26-13	5214-5215	,	_	_	
26-14	5216-5221	Table	_	_	
26-15	5222-5223	1	_	_	
26-16	5224-5226	is	_	_	
26-17	5227-5236	presented	_	_	
26-18	5236-5237	.	_	_	
